# Schrodinger, Inc. (SDGR) Stock Analysis: A Look at 108.77% Potential Upside and Investor Ratings

- Link: https://www.directorstalkinterviews.com/schrodinger-inc-sdgr-stock-analysis-a-look-at-108-77-potential-upside-and-investor-ratings/4121247392
- Published: 2026-03-31T10:16:11+01:00
- Author: Madison Wilson

Schrodinger, Inc. (NASDAQ: SDGR) operates at the cutting-edge intersection of technology
and healthcare, leveraging its proprietary computational platform to revolutionize
drug discovery and materials science. As investors evaluate the potential of this
healthcare innovator, several key metrics and insights stand out, signaling both
opportunities and challenges for those considering a stake in the company.

#### Company and Market Overview

Based in New York, Schrodinger is a notable player in the Health Information Services
industry, with operations spanning the globe. Despite a modest market capitalization
of $817.24 million, the company’s dual focus on software and drug discovery positions
it uniquely within the healthcare sector. The Software segment, known for its transformative
applications in molecular discovery, caters to the life sciences and materials science
industries. Meanwhile, the Drug Discovery segment is focused on developing a robust
pipeline of preclinical and clinical programs, boasting collaborations with major
players like Novartis Pharma AG.

#### Current Price and Historical Performance

Trading at $11.07, Schrodinger’s stock reflects a significant retreat from its 52-
week high of $26.69. Despite this decline, the stock’s current price mirrors the
lower bound of its 52-week range, highlighting potential volatility. The company’s
trailing price-to-earnings ratio is unavailable, while its forward P/E ratio stands
at -8.02, indicating expectations of continued losses in the near term. The negative
EPS of -1.41 further underscores this, yet the company’s substantial free cash flow
of nearly $100 million offers a silver lining, suggesting financial agility to sustain
operations and fuel future growth.

#### Growth Prospects and Financial Health

Revenue growth has faced challenges, with a slight contraction of -1.20%. This tepid
performance might concern some investors, especially when coupled with a return 
on equity of -26.29%. However, Schrodinger’s free cash flow strength provides a 
counterbalance, offering liquidity to navigate market headwinds and invest in strategic
initiatives.

#### Analyst Ratings and Price Target

Analysts paint an optimistic picture for Schrodinger, with seven buy ratings and
two hold ratings, and no sell recommendations. The consensus reflects confidence
in the company’s long-term potential, bolstered by a robust average target price
of $23.11. This suggests an impressive potential upside of 108.77% from current 
levels, presenting a compelling case for growth-oriented investors.

#### Technical Indicators

The technical landscape for Schrodinger reveals mixed signals. The stock trades 
below both its 50-day and 200-day moving averages, at $12.96 and $17.91 respectively,
indicating potential bearish momentum. However, the Relative Strength Index (RSI)
of 70.55 suggests the stock is approaching overbought territory, a possible precursor
to upward price adjustments. Additionally, the MACD and signal line figures, at -
0.49 and -0.43 respectively, point to a cautious sentiment among traders.

#### Strategic Outlook

Investors considering Schrodinger should weigh the innovative potential of its computational
platform against the financial and operational challenges it faces. The company’s
advancements in drug discovery, supported by strategic partnerships like that with
Novartis, represent significant upside potential. However, the path to profitability
remains uncertain, and prospective shareholders should be prepared for inherent 
risks, including market volatility and ongoing financial losses.

In light of these factors, Schrodinger, Inc. remains a fascinating proposition for
investors with an appetite for risk and a belief in the transformative power of 
computational drug discovery. As the company continues to navigate its growth trajectory,
its ability to leverage strategic partnerships and maintain cash flow will be critical
in realizing its potential.

Share on: